A5056315538- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Peptidase Inhibition and Analysis
- Tryptophan and brain disorders
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Ubiquitin and proteasome pathways
- Chronic Lymphocytic Leukemia Research
- Adolescent and Pediatric Healthcare
- Epigenetics and DNA Methylation
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Hepatitis C virus research
- Sarcoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Genomic variations and chromosomal abnormalities
- Retinoids in leukemia and cellular processes
- Cardiac tumors and thrombi
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cancer Genomics and Diagnostics
Nagoya City University
2015-2024
Tokyo Medical and Dental University
2022-2024
National Center For Child Health and Development
2022-2024
Toyokawa City Hospital
2022-2023
Nagoya City University Hospital
2016-2018
Mizuho (Japan)
2015
Indoleamine 2,3-dioxygenase 1 (IDO1: IDO), an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway, is increasingly being recognized as important microenvironmental factor suppressing antitumor immune responses. The purpose of present study was to determine prognostic significance Trp catabolism in adult T-cell leukemia/lymphoma (ATL).We quantified serum and Kyn 96 ATL patients, 38 human lymphotropic virus type-1 asymptomatic carriers (HTLV-1 ACs), 40 healthy volunteer...
Abstract Background Invasive fungal infections (IFIs) represent a potentially fatal complication in patients who undergo allogeneic hematopoietic stem cell transplantation (HSCT) if the initiation of therapy is delayed. Some guidelines recommend antifungal prophylaxis or preemptive for these depending on risk IFIs following HSCT. This retrospective study aimed to identify group safely HSCT with low‐dose fluconazole (FLCZ) (100 mg/day). Methods We retrospectively reviewed 107 underwent their...
Adult T‐cell leukemia/lymphoma ( ATL ) is caused by Human lymphotropic/leukemia virus type 1 HTLV ‐1), and a higher ‐1 provirus load in PBMC risk factor for development. Here, we document significant inverse correlation between the function of Tax‐specific CTL (Tax‐ ), as assessed ex vivo cytokine production response to cognate peptide, both asymptomatic carriers AC (Spearman rank coefficient [ R s] = −0.494, P .037, n 18) patients s −0.774, .001, 15). There was also percentage PD...
Indoleamine 2,3‐dioxygenase 1 (IDO) is an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway. The purpose of present study was to determine clinical significance Trp catabolism in newly diagnosed Hodgkin lymphoma (HL) patients. We quantified serum and Kyn 52 HL patients, analyzed their associations with different parameters including soluble CD30 concentration. IDO expression evaluated patients’ affected lymph nodes. cohort comprised 22 male 30 female patients (age range,...
Bortezomib (Btz) is an active agent used to treat multiple myeloma (MM). Not all patients who receive Btz-containing therapy show a favorable response. Interaction of cellular adhesion molecules with MM and bone marrow stromal cells crucial for the survival cells. However, little known about role these in sensitivity therapy. Thus, we evaluated correlation between level efficacy Btz plus dexamethasone (Bd) The expression neural cell molecule gene (NCAM, also as CD56), ITGA4, CXCR4, other...
Cereblon (CRBN) is a target for immunomodulatory drugs. This study investigated the prognostic value of expression CRBN-pathway genes on clinical relevance lenalidomide (Len) treatment and evaluated levels CRBN-binding proteins mutations in these after Len treatment. Forty-eight primary multiple myeloma cells were collected prior to with dexamethasone (Ld) 25 paired samples obtained post-Ld therapy. These tumor used determine mutated forms genes. Following normalization CRBN levels, there...
The clinical efficacy and outcomes of pazopanib treatment for metastatic extraosseous Ewing sarcoma remain unclear. We herein report a case heavily pre-treated in which achieved significant improvement. A 17-year-old girl was referred to our hospital due sarcoma. initial cytotoxic chemotherapy temporarily effective, however, her disease eventually progressed, she subsequently treated with pazopanib. recurrent tumor showed marked response therapy; the therapeutic effect has lasted more than...
A 72-year-old female complaining of back pain was diagnosed with IgG-κ multiple myeloma. After osteosynthesis for fracture the left femoral shaft due to myeloma, she received bortezomib, melphalan, and prednisolone as an initial regimen but discontinued it after three courses progressive disease. The patient subsequently lenalidomide dexamethasone a second-line 2.5 years, pomalidomide third-line only 2 months. An anti-CD38 monoclonal antibody, daratumumab (DARA), bortezomib (DVd) fourth-line...
BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility for treating natural killer (NK) cell leukemias/lymphomas that poor prognosis, namely extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia, in preclinical mouse model vivo as well tissue culture models vitro. Seven leukemia/lymphoma lines primary leukemia cells from two individual...
Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as monotherapy against hematological malignancies and is expected to be used in combination with standard therapies for multiple myeloma (MM). To develop more effective less toxic immunomodulatory drugs (IMiDs) therapy, antitumor effect sub-optimal doses AFU, pomalidomide plus dexamethasone (PD), AFU-PD on MM cells were examined present study. Two cell lines, XG-7 U266, low sensitivity both PD AFU...
Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem transplantation PCD, cases during anti-CD38 mAb therapy recently. Due to limited studies, we aimed determine frequency and...
Abstract Multiple myeloma (MM) is an incurable B‐cell malignancy often accompanied by profound immunodeficiency. Lenalidomide (Len) immunomodulatory drug that exerts promising therapeutic effects on MM through the immune system. However, predictive markers related to of Len treatment are not fully understood. This study aimed identify candidate biomarkers for predicting clinical efficacy and dexamethasone (Ld) therapy a comprehensive analysis serum cytokines. The levels 48 cytokines in...
Proteasome inhibitors (PI), mainly targeting the β5 subunit of 20S proteasome, are widely used in treatment multiple myeloma (MM). However, PI resistance remains an unresolved problem therapy relapsed and refractory MM. To develop a new that targets other proteasome subunits, we examined anti-MM activity novel syringolin analog, syringolog-1, which inhibits both β2 subunits. Syringolog-1 exhibited marked cytotoxicity against various MM cell lines anti-tumor towards bortezomib (Btz)-resistant...
Abstract The enzyme, indoleamine 2,3‐dioxygenase 1 (IDO), catabolizes tryptophan (Trp) in the kynurenine (Kyn) pathway, and is important suppressing antitumor immune responses tumor microenvironment. With regard to previously untreated patients with follicular lymphoma (FL), we sought establish prognostic significance of Trp catabolism this disease. Serum Kyn levels 110 FL were quantified, their relationship different clinical parameters studied. IDO expression lymph nodes affected was Study...
Supportive care is a critical issue especially for patients with cancer of unknown primary since they often face serious situations, continuing to seek relevant diagnosis and treatment the sites unknown. However, there are only few research reports on this subject. The aim study was clarify experience until have their initial obtain suggestions supportive them.A qualitative using semi-structured interviews regarding conducted.Data nine were collected by interviews. Patients' speech at...